Please use this identifier to cite or link to this item:
|Title:||HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?||Authors:||Hompes, D.
Van Cutsem, E.
|Issue Date:||2012||Publisher:||OXFORD UNIV PRESS||Source:||ANNALS OF ONCOLOGY, 23 (12), p. 3123-3129||Abstract:||Adequate estimation of the potential benefits of 'adjuvant' hyperthermia and intraperitoneal chemotherapy (HIPEC) in T4 patients through assessment of the burden of peritoneal carcinomatosis (PC) in T4 tumors and the risk of PC as the only metastatic site. Analysis of prospectively collected data on patients who underwent surgery for colon cancer (Jan 2004-Jan 2007). About 379 patients (M/F = 204/175) were included, with a median age of 71.8 years (range 35.4-95.0): 39 stage I, 126 stage II, 89 stage III, 116 stage IV disease (+9 with unknown stage). The median follow-up was 34.8months [range 0.0-79.4]. The 3- and 5-year overall survival rates (OS) were 68.4% (95% confidence interval (CI) 63.9%-72.4%) and 60.3% (95%CI 55.6%-64.7%). Relapse analysis was restricted to stages II-III T3 (N = 154) and T4 tumors (N = 19) with complete relapse data, of which 13.2% developed PC. PC has a detrimental effect on OS [HR 6.3 (95%CI: 3.1-13.0, P < 0.0001)]. 50% of T4a and 20% of T4b developed PC. The 1- and 3-year PC percentage was significantly lower for T3 (4.5% and 9.3%) than T4 tumors (15.6% and 36.7%) (P = 0.008). PC was the only metastatic site in 3/15 T3 [proportion 0.20, 95%CI (0.043-0.481)] and 5/8 T4 tumors with PC [proportion 0.625, 95%CI (0.245-0.915)] (P = 0.071). T4a colon tumors have a significantly higher risk of developing PC. Twenty-five percent (5/19) of stages II-III T4 tumors develop PC as the only metastatic site. This could define the possible window of opportunity for adjuvant HIPEC to prevent PC.||Notes:||[Hompes, D.; Tiek, J.; Wolthuis, A.; Penninckx, F.; D'Hoore, A.] Univ Hosp Gasthuisberg, Dept Abdominal Surg, Louvain, Belgium. [Van Cutsem, E.] Katholieke Univ Leuven, Dept Digest Oncol, Louvain, Belgium. [Fieuws, S.; Van Cutsem, E.] Univ Hasselt, Louvain, Belgium. [Fieuws, S.] Univ Hosp Gasthuisberg Leuven, Dept Digest Oncol, B-3000 Louvain, Belgium. email@example.com||Keywords:||adjuvant; colon cancer; HIPEC; oncologic outcome; T4a;Oncology; adjuvant; colon cancer; HIPEC; oncolic outcome; T4a||Document URI:||http://hdl.handle.net/1942/14503||ISSN:||0923-7534||e-ISSN:||1569-8041||DOI:||10.1093/annonc/mds173||ISI #:||000311642100019||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2013|
|Appears in Collections:||Research publications|
Show full item record
checked on Sep 3, 2020
WEB OF SCIENCETM
checked on May 21, 2022
checked on May 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.